News | February 02, 2010

Image Reconstruction Software Helps Reduce Dose in Nuclear Cardiology

Image Reconstruction Software Helps Reduce Dose in Nuclear Cardiology

February 2, 2010 - Two protocols for reduced-dose cardiac imaging, without compromising image quality, may help enhance the performance of gamma cameras by shortening acquisition times, enabling reduced radiopharmaceutical doses and increasing image resolution. Nuclear medicine image reconstruction software maker UltraSPECT said its imaging protocols minimize radiation exposure to patients and staff, in addition to mitigating the impact of the technetium-99 (Tc-99m ) isotope shortage. The company’s FDA-cleared and CE mark-approved Xpress.Cardiac and Xpress3.Cardiac products allow the utilization of lower dose imaging protocols with no compromise in imaging acquisition times and outcomes. UltraSPECT products feature connectivity to the imaging systems of all three major nuclear medicine camera manufacturers, supporting most existing camera hardware and workstation versions. With the Xpress.Cardiac clinicians can apply the one-day rest/stress protocol, with scan times as defined by the ASNC recommendations, but with injected doses that are approximately half the doses specified by ASNC: rest: 5-6 mCi; 8-9 mCi for patients weighing more than 100 kg. Stress: 15-20 mCi; 24-27 mCi for patients weighing more than 100 kg. With the Xpress3.Cardiac physicians can apply two different protocols: the half-dose, half-time single-day rest/stress protocol, or the dual-isotope, single-day protocol. The half-dose, half-time protocol combines reduced injection doses with shortened scan times, enabling higher patient safety and comfort, while helping overcome the impact of radioisotope supply shortages and increasing patient throughput. A typical half-dose half-time same-day Tc-99m rest/stress protocol consists of: rest 5-6 mCi; 15-20 seconds per stop. Stress: 15-20 mCi; 10 seconds per stop. The one-day dual-isotope Tl-201/Tc-99m protocol combines reduced doses and shorter scan times. Reduced-dose shorter-time Rest Tl-201 imaging is followed by shorter-time reduced-dose Tc-99m stress imaging: rest: Tl-201, 2 mCi (female)/3 mCi (male); 20 seconds per stop. Stress: Tc-99m, 20 mCi (female)/30 mCi (male); 10 seconds per stop. Many users of the dose-reduction protocols enabled by UltraSPECT's image reconstruction products said they have not been impacted by the reactor shutdowns due to the more effective utilization of their limited technetium supplies. "WBR technology has been instrumental in maintaining our high patient throughput throughout the technetium shortage. With half-dose imaging performed on nearly 1,000 patients in our clinic, we have managed to minimize the effect of the reduced supply," said James Reibsane, CNMT, director of diagnostic and technical services at Berks Cardiologists Ltd., Wyomissing, Pa. UltraSPECT’s Xpress.Cardiac, Xpress3.Cardiac, and Xpress/Xact.Bone products are distributed in the United States by Cardinal Health. For more information: www.cardinalhealth.com, www.ultraspect.com

Related Content

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | April 30, 2021
April 30, 2021 — In almost 10 percent of...
Spectral DLR enables improved assessment of lumen stenosis in the presence of calcified plaque. Interactive monochromatic image display enables improved opacification of the injected contrast with low keV images and reduced calcium blooming artifacts with high keV images

Spectral DLR enables improved assessment of lumen stenosis in the presence of calcified plaque. Interactive monochromatic image display enables improved opacification of the injected contrast with low keV images and reduced calcium blooming artifacts with high keV images. The range of monochromatic energy levels (35-135 keV) can be visualized in real time through an image slider in the application that can be integrated in to a PACS.

News | Cardiac Imaging | April 21, 2021
April 21, 2021 — Meeting the growing cardiovascular needs of healthcare providers today, ...
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Getty Images

News | PET Imaging | April 19, 2021
April 19, 2021 — Molecular Targeting Technologies, Inc.
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging | April 19, 2021
April 19, 2021 — The preliminary...